Scinai Immunotherapeutics Stock Set to Reverse Split on Thursday, November 19th (NASDAQ:SCNI)

Shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) are going to reverse split before the market opens on Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 18th.

SCNI opened at $0.48 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.56. The business has a 50 day moving average price of $1.20 and a 200 day moving average price of $4.19. Scinai Immunotherapeutics has a twelve month low of $0.39 and a twelve month high of $13.00.

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.80. The company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.49 million.

Separately, Weiss Ratings raised Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.
• Five stocks we like better than Scinai Immunotherapeutics
• Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
• Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
• Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching

Receive News & Ratings for Scinai Immunotherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.…Read more by Mark Dietrich